ResearcherCancer Research UK Scotland InstituteNo recent work listed

Vassilis Papalazarou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3206-401X; OpenAlex author ID A5037840671. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 3

Collagen VI expression is negatively mechanosensitive in pancreatic cancer cells and supports the metastatic niche. Co-author DOI 10.1242/jcs.259978 ↗
The creatine-phosphagen system is mechanoresponsive in pancreatic adenocarcinoma and fuels invasion and metastasis. Co-author DOI 10.1038/s42255-019-0159-z ↗
ECM mechanics and spatiotemporal energetics in pancreatic cancer Co-author DOI 10.5525/gla.thesis.78985 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Amélie Juin · 2 shared papers, 2020–2022 · strength 0.28
- Paper Collagen VI expression is negatively mechanosensitive in pancreatic cancer cells and supports the metastatic niche. DOI 10.1242/jcs.259978 ↗
- Paper The creatine-phosphagen system is mechanoresponsive in pancreatic adenocarcinoma and fuels invasion and metastasis. DOI 10.1038/s42255-019-0159-z ↗
Laura M. Machesky · 2 shared papers, 2020–2022 · strength 0.28
- Paper Collagen VI expression is negatively mechanosensitive in pancreatic cancer cells and supports the metastatic niche. DOI 10.1242/jcs.259978 ↗
- Paper The creatine-phosphagen system is mechanoresponsive in pancreatic adenocarcinoma and fuels invasion and metastasis. DOI 10.1038/s42255-019-0159-z ↗
James Drew · 1 shared paper, 2022 · strength 0.16
- Paper Collagen VI expression is negatively mechanosensitive in pancreatic cancer cells and supports the metastatic niche. DOI 10.1242/jcs.259978 ↗
Oliver D.K. Maddocks · 1 shared paper, 2020 · strength 0.12
- Paper The creatine-phosphagen system is mechanoresponsive in pancreatic adenocarcinoma and fuels invasion and metastasis. DOI 10.1038/s42255-019-0159-z ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.